Mollie Roth, Esq.
Corporate Counsel, Vice President of Business Development Diaceutics

In her role at Diaceutics, Mollie Roth combines over 10 years of experience in complex patent and product liability litigation for the pharmaceutical industry with her background as a research scientist to focus on the pharmacolegal and regulatory environment surrounding the personalized medicine industry and its evolving business dynamic.

Diaceutics, an international change management and consulting firm specializing in personalized medicine, provides pharmaceutical industry leaders with the foundation and operational structure needed to effectively develop and commercialize targeted therapies to improve overall return on investment . Utilizing its accumulated PM knowledge, specialist team, and “fit for purpose” decision tools, Diaceutics aims to help remove internal roadblocks to leadership in the PM space.

Prior to joining Diaceutics, Roth was a member of the litigation and life sciences groups at Kaye Scholer in New York City and then Nixon Peabody in Washington, D.C. Prior to attending law school, she ran a research laboratory at Oregon State University’s College of Pharmacy focused on the role of amino acids in the body’s regulation and mediation of pain.

Roth holds a B.A. in neuropsychopharmacology from Rutgers University and a J.D. from Vermont Law School. She is currently pursuing an L.LM in Biotechnology and Genomics at the Sandra Day O’Connor College of Law at Arizona State University where she is also a visiting faculty fellow in the Center for the Study of Law, Science, & Technology.

Roth is affiliated with several professional organizations and recently served on the organizing committee for the DIA/FDA fourth annual workshop in a series on pharmacogenomics, “Biomarkers and Pharmacogenomics in Drug Development and Regulatory Decision Making,” held December 10-12, 2007, in Bethesda, Md.